Healthcare leaders report precision medicine is becoming a clinical standard as AI tools emerge as "digital co-workers" and breakthroughs in biomarkers move beyond specialized oncology into primary care settings.
The global AI in biotechnology market was valued at USD 1,033 million in 2024 and is projected to reach USD 1,971 million by 2031, growing at a CAGR of 10.6%. A separate AI in precision medicine market is forecast to reach $38.88 billion by 2034 with a 35.5% CAGR.
Generative AI is evolving from pilot projects to a foundational tool in life sciences, driving an estimated $60 billion to $110 billion in annual economic impact while accelerating drug discovery, reducing clinical trial timelines, and improving operational efficiency across the pharmaceutical sector.
The Emirates Drug Establishment unveiled the InSilico Medicine project at World Health Expo 2026, using AI and digital models to reduce drug development costs and accelerate pharmaceutical research. EDE signed an MoU with InSilico Medicine AI Limited to formalize the collaboration.
